Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial

Aird, 1995, Quality assurance in the CHART clinical trial, Radiother. Oncol., 36, 235, 10.1016/0167-8140(95)01598-B

Ball, 1995, A phase III study of accelerated radiotherapy with and without carboplatin in non-small cell lung cancer: an interim toxicity analysis of the first 100 patients, Int. J. Radiat. Oncol. Biol. Phys., 31, 267, 10.1016/0360-3016(94)E0021-B

Ball, 1996, A phase III study of conventional and accelerated radiotherapy (RT) with and without carboplatin in unresectable non small cell lung cancer (NSCLC), Radiother. Oncol., 40(Suppl. 10), S61, 10.1016/S0167-8140(96)80240-4

Komaki, 1997, Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06, Am. J. Clin. Oncol., 20, 435, 10.1097/00000421-199710000-00002

Cox, 1993, Interruptions of high dose radiation therapy decrease long term survival of favorable patients with unresectable non small cell carcinoma of the lung: analysis of 1244 cases from three Radiation Therapy Oncology Group (RTOG) Trials, Int. J. Radiat. Oncol. Biol. Phys., 27, 493, 10.1016/0360-3016(93)90371-2

Dillman, 1993, Randomized trial of induction chemotherapy plus radiation therapy vs. radiation therapy alone in stage III non small cell lung cancer: five-year follow-up of CALGB 84-33, Proc. Am. Soc. Clin. Oncol., 12, 329

Dische, 1989, Continuous, hyperfractionated, accelerated radiotherapy (CHART): an interim report upon late morbidity, Radiother. Oncol., 16, 65, 10.1016/0167-8140(89)90071-6

Dische, 1999, The CHART regimen and morbidity, Acta Oncol., 38, 147, 10.1080/028418699431546

Dische, 1990, The rationale for continuous, hyperfractionated, accelerated radiotherapy (CHART), Int. J. Radiat. Oncol. Biol. Phys., 19, 1317, 10.1016/0360-3016(90)90251-E

Dische, 1997, A randomised multicentre trial of CHART vs. conventional radiotherapy in head and neck cancer, Radiother. Oncol., 44, 123, 10.1016/S0167-8140(97)00094-7

Drummond, 1997, Clin. Oncol., 9, 313, 10.1016/S0936-6555(05)80065-2

Green, 1994, Endpoints for multimodal clinical trials in stage III non-small cell lung cancer (NSCLC): a consensus report, Lung Cancer; 11, 11 (Suppl.3), S11, 10.1016/0169-5002(94)91859-7

Komaki, 1997, Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588, Int. J. Radiat. Oncol. Biol. Phys., 39, 537, 10.1016/S0360-3016(97)00365-9

Le Chevalier, 1991, Radiotherapy alone vs. combined chemotherapy and radiotherapy in non-resectable non-small cell lung cancer: first analysis of a randomized trial in 353 patients, J. Natl. Cancer Inst., 83, 417, 10.1093/jnci/83.6.417

Morton, 1991, Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small-cell lung cancer, Ann. Intern. Med., 115, 681, 10.7326/0003-4819-115-9-681

Munroe, 1998, Commentary: what now for postoperative radiotherapy for lung cancer?, Lancet, 352, 250, 10.1016/S0140-6736(98)22030-7

Non-small Cell Lung Cancer Collaborative Group, 1995, Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials, Br. Med. J., 311, 899, 10.1136/bmj.311.7010.899

Parmar, 1994, The CHART Trials: Bayesian design and monitoring in practice, Stat. Med., 13, 1297, 10.1002/sim.4780131304

Parmar, 1995

Perez, 1980, A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung, Cancer, 45, 2744, 10.1002/1097-0142(19800601)45:11<2744::AID-CNCR2820451108>3.0.CO;2-U

Port Meta-analysis Trialists Group, 1998, Postoperative radiotherapy in non-small cell lung cancer: systemic review and meta-analysis of individual patient data from nine randomised controlled trials, Lancet, 352, 257, 10.1016/S0140-6736(98)06341-7

Robertson, 1999, Overall treatment time and the conventional arm of the CHART Trial in the radiotherapy of head and neck cancer, Radiother. Oncol., 50, 25, 10.1016/S0167-8140(98)00116-9

Saunders, 1986, Radiotherapy employing three fractions in each day over a continuous period of 12 days, Br. J. Radiol., 59, 523, 10.1259/0007-1285-59-701-523

Saunders, 1990, Continuous, hyperfractionated, accelerated radiotherapy (CHART) in non-small cell carcinoma of the bronchus, Int. J. Radiat. Oncol. Biol. Phys., 19, 1211, 10.1016/0360-3016(90)90231-8

Saunders, 1991, Is control of the primary tumour worthwhile in non-oat cell carcinoma of the bronchus, Clin. Oncol., 3, 185, 10.1016/S0936-6555(05)80736-8

Saunders, 1996, On behalf of CHART Steering Committee: randomised multicentre trials of CHART vs. conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report, Br. J. Cancer, 73, 1455, 10.1038/bjc.1996.276

Saunders, 1997, On behalf of the CHART Steering Committee: continuous hyperfractionated accelerated radiotherapy (CHART) vs. conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial, Lancet, 350, 161, 10.1016/S0140-6736(97)06305-8

Sause, 1995, Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced unresectable non-small-cell lung cancer, J. Natl. Cancer Inst., 87, 198, 10.1093/jnci/87.3.198

Smith, 1993, Commentary: efficacy of cost-effectiveness of cancer treatment: allocation of resources based on decision analysis, J. Natl. Cancer Inst., 85, 1460, 10.1093/jnci/85.18.1460